Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Role of inflammation and behavior in CRF for early breast cancer survivors

Antonio Di Meglio • 13 Sep 2024
ESMO 2024
Breast Cancer

Antonio Di Meglio, MD, PhD, Institut Gustave Roussy, Villejuif, France, gives an overview of a biobehavioral model under development to predict cancer-related fatigue (CRF) among early-stage breast cancer survivors, utilizing systemic inflammation markers. Potential factors include pre-treatment fatigue, younger age, smoking, and symptoms like pain and insomnia. Patients with elevated pre-treatment IL-6 also experienced greater CRF two years post-diagnosis, highlighting an association between IL-6 and unhealthy behaviors. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Antonio Di Meglio

Associations between inflammation, behaviors, and CRF in breast cancer survivors
1:00
Associations between inflammation, behaviors, and CRF in breast cancer survivors
Antonio Di Meglio • 13 Sep 2024
Managing post-treatment fatigue in breast cancer with behavioral interventions
0:46
Managing post-treatment fatigue in breast cancer with behavioral interventions
Antonio Di Meglio • 13 Sep 2024
Precision survivorship medicine in breast cancer
3:32
Precision survivorship medicine in breast cancer
Antonio Di Meglio • 26 Mar 2024
Improving breast cancer outcomes with exercise
5:04
Improving breast cancer outcomes with exercise
Antonio Di Meglio • 26 Mar 2024

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals